Further increase in Rxs for Roche's Xenical
A total of 96,485 prescriptions were dispensed in the USA forHoffmann-La Roche's new anti-obesity drug Xenical (orlistat) in the four weeks since launch, reports IMS Health. For the week ending May 21, dispensed mail-order prescriptions for Xenical totaled 440, and 73% of Xenical prescriptions filled in that week were paid for in cash, with 27% covered by a third-party payer. This compares to an overall industry average of 67% third-party payer coverage, says IMS.
Prescriptions for Knoll's Meridia (sibutramine), the newest anti-obesity drug before Xenical, totaled 7,157 in its fourth week on the market and did not reach a 30,000 weekly total until its thirteenth week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze